RxDoctor Payments Data

Philip Cuva, OD

Optometrist · Tampa, FLNPI 1407960073

Payments from drug & device makers

$1,810in general payments, 2019–2025

Across 81 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$438
  • AbbVie$422
  • Alcon$205
  • Bausch & Lomb Americas Inc.$179
  • Sun Pharmaceutical Industries Inc.$133
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$110
  • plus $322 from 8 others

What the payments were for

  • Food & beverage$1,810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,810 in reported general payments places this provider in the 65th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$30,400
Medicare patients
180
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost244$111,752
RestasisCyclosporine68$70,755
CombiganBrimonidine Tartrate/Timolol169$56,180
Latanoprost2,841$26,036
Travoprost173$25,194
Brimonidine Tartrate639$24,989
VyzultaLatanoprostene Bunod71$23,366
RhopressaNetarsudil Mesylate47$17,230
XiidraLifitegrast17$16,472
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat668$10,661
Timolol Maleate519$9,012
Prednisolone Acetate161$8,499
Alphagan PBrimonidine Tartrate20$6,046
RocklatanNetarsudil Mesylat/Latanoprost11$5,003
Dorzolamide Hcl209$3,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$422$244,732501 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$179$39,83788 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$69$22,23358 claims
AlconAzopt$205$3,42812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →